Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants
Status:
Active, not recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this randomized and placebo-controlled EpoRepair trial is to evaluate the
effect of intravenously administered recombinant human erythropoietin (Epo) as compared to
placebo in preterm infants with brain damage on neurological development until five years od
age.